Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.

The purpose of the present study was to develop and assess a novel sustained-release drug delivery system of Bimatoprost (BIM). Chitosan polymeric inserts were prepared using the solvent casting method and characterized by swelling studies, infrared spectroscopy, differential scanning calorimetry, d...

Full description

Bibliographic Details
Main Authors: Juçara Ribeiro Franca, Giselle Foureaux, Leonardo Lima Fuscaldi, Tatiana Gomes Ribeiro, Lívia Bomfim Rodrigues, Renata Bravo, Rachel Oliveira Castilho, Maria Irene Yoshida, Valbert Nascimento Cardoso, Simone Odília Fernandes, Sebastião Cronemberger, Anderson José Ferreira, André Augusto Gomes Faraco
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4005758?pdf=render
_version_ 1819327321430032384
author Juçara Ribeiro Franca
Giselle Foureaux
Leonardo Lima Fuscaldi
Tatiana Gomes Ribeiro
Lívia Bomfim Rodrigues
Renata Bravo
Rachel Oliveira Castilho
Maria Irene Yoshida
Valbert Nascimento Cardoso
Simone Odília Fernandes
Sebastião Cronemberger
Anderson José Ferreira
André Augusto Gomes Faraco
author_facet Juçara Ribeiro Franca
Giselle Foureaux
Leonardo Lima Fuscaldi
Tatiana Gomes Ribeiro
Lívia Bomfim Rodrigues
Renata Bravo
Rachel Oliveira Castilho
Maria Irene Yoshida
Valbert Nascimento Cardoso
Simone Odília Fernandes
Sebastião Cronemberger
Anderson José Ferreira
André Augusto Gomes Faraco
author_sort Juçara Ribeiro Franca
collection DOAJ
description The purpose of the present study was to develop and assess a novel sustained-release drug delivery system of Bimatoprost (BIM). Chitosan polymeric inserts were prepared using the solvent casting method and characterized by swelling studies, infrared spectroscopy, differential scanning calorimetry, drug content, scanning electron microscopy and in vitro drug release. Biodistribution of 99mTc-BIM eye drops and 99mTc-BIM-loaded inserts, after ocular administration in Wistar rats, was accessed by ex vivo radiation counting. The inserts were evaluated for their therapeutic efficacy in glaucomatous Wistar rats. Glaucoma was induced by weekly intracameral injection of hyaluronic acid. BIM-loaded inserts (equivalent to 9.0 µg BIM) were administered once into conjunctival sac, after ocular hypertension confirmation. BIM eye drop was topically instilled in a second group of glaucomatous rats for 15 days days, while placebo inserts were administered once in a third group. An untreated glaucomatous group was used as control. Intraocular pressure (IOP) was monitored for four consecutive weeks after treatment began. At the end of the experiment, retinal ganglion cells and optic nerve head cupping were evaluated in the histological eye sections. Characterization results revealed that the drug physically interacted, but did not chemically react with the polymeric matrix. Inserts sustainedly released BIM in vitro during 8 hours. Biodistribution studies showed that the amount of 99mTc-BIM that remained in the eye was significantly lower after eye drop instillation than after chitosan insert implantation. BIM-loaded inserts lowered IOP for 4 weeks, after one application, while IOP values remained significantly high for the placebo and untreated groups. Eye drops were only effective during the daily treatment period. IOP results were reflected in RGC counting and optic nerve head cupping damage. BIM-loaded inserts provided sustained release of BIM and seem to be a promising system for glaucoma management.
first_indexed 2024-12-24T13:08:59Z
format Article
id doaj.art-39e25685b2524a57ba662d9214c0c86c
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-24T13:08:59Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-39e25685b2524a57ba662d9214c0c86c2022-12-21T16:53:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9546110.1371/journal.pone.0095461Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.Juçara Ribeiro FrancaGiselle FoureauxLeonardo Lima FuscaldiTatiana Gomes RibeiroLívia Bomfim RodriguesRenata BravoRachel Oliveira CastilhoMaria Irene YoshidaValbert Nascimento CardosoSimone Odília FernandesSebastião CronembergerAnderson José FerreiraAndré Augusto Gomes FaracoThe purpose of the present study was to develop and assess a novel sustained-release drug delivery system of Bimatoprost (BIM). Chitosan polymeric inserts were prepared using the solvent casting method and characterized by swelling studies, infrared spectroscopy, differential scanning calorimetry, drug content, scanning electron microscopy and in vitro drug release. Biodistribution of 99mTc-BIM eye drops and 99mTc-BIM-loaded inserts, after ocular administration in Wistar rats, was accessed by ex vivo radiation counting. The inserts were evaluated for their therapeutic efficacy in glaucomatous Wistar rats. Glaucoma was induced by weekly intracameral injection of hyaluronic acid. BIM-loaded inserts (equivalent to 9.0 µg BIM) were administered once into conjunctival sac, after ocular hypertension confirmation. BIM eye drop was topically instilled in a second group of glaucomatous rats for 15 days days, while placebo inserts were administered once in a third group. An untreated glaucomatous group was used as control. Intraocular pressure (IOP) was monitored for four consecutive weeks after treatment began. At the end of the experiment, retinal ganglion cells and optic nerve head cupping were evaluated in the histological eye sections. Characterization results revealed that the drug physically interacted, but did not chemically react with the polymeric matrix. Inserts sustainedly released BIM in vitro during 8 hours. Biodistribution studies showed that the amount of 99mTc-BIM that remained in the eye was significantly lower after eye drop instillation than after chitosan insert implantation. BIM-loaded inserts lowered IOP for 4 weeks, after one application, while IOP values remained significantly high for the placebo and untreated groups. Eye drops were only effective during the daily treatment period. IOP results were reflected in RGC counting and optic nerve head cupping damage. BIM-loaded inserts provided sustained release of BIM and seem to be a promising system for glaucoma management.http://europepmc.org/articles/PMC4005758?pdf=render
spellingShingle Juçara Ribeiro Franca
Giselle Foureaux
Leonardo Lima Fuscaldi
Tatiana Gomes Ribeiro
Lívia Bomfim Rodrigues
Renata Bravo
Rachel Oliveira Castilho
Maria Irene Yoshida
Valbert Nascimento Cardoso
Simone Odília Fernandes
Sebastião Cronemberger
Anderson José Ferreira
André Augusto Gomes Faraco
Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
PLoS ONE
title Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
title_full Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
title_fullStr Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
title_full_unstemmed Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
title_short Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
title_sort bimatoprost loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment in vitro and in vivo evaluation
url http://europepmc.org/articles/PMC4005758?pdf=render
work_keys_str_mv AT jucararibeirofranca bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT gisellefoureaux bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT leonardolimafuscaldi bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT tatianagomesribeiro bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT liviabomfimrodrigues bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT renatabravo bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT racheloliveiracastilho bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT mariaireneyoshida bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT valbertnascimentocardoso bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT simoneodiliafernandes bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT sebastiaocronemberger bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT andersonjoseferreira bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation
AT andreaugustogomesfaraco bimatoprostloadedocularinsertsassustainedreleasedrugdeliverysystemsforglaucomatreatmentinvitroandinvivoevaluation